Identification and Functional Characterization of FMN2, a Regulator of the Cyclin-Dependent Kinase Inhibitor p21

Molecular Cell

Volumn 49, Issue 5, 2013, Pages 922-933

  Yamada, Kayo ^a   Ono, Motoharu ^a   Perkins, Neil D ^b   Rocha, Sonia ^a   Lamond, Angus I ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P21; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; HYPOXIA; MASS SPECTROMETRY; NUCLEOLUS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TRANSPORT;

CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEOLUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MASS SPECTROMETRY; NERVE TISSUE PROTEINS; NF-KAPPA B; PROTEOMICS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF;

MAMMALIA;

EID: 84876864559     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2012.12.023     Document Type: Article

References (50)

1. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
2. Andersen J.S., Lyon C.E., Fox A.H., Leung A.K., Lam Y.W., Steen H., Mann M., Lamond A.I. Directed proteomic analysis of the human nucleolus. Curr. Biol. 2002, 12:1-11.
3. Andersen J.S., Lam Y.W., Leung A.K., Ong S.E., Lyon C.E., Lamond A.I., Mann M. Nucleolar proteome dynamics. Nature 2005, 433:77-83.
4. Badal V., Menendez S., Coomber D., Lane D.P. Regulation of the p14ARF promoter by DNA methylation. Cell Cycle 2008, 7:112-119.
5. Boisvert F.M., van Koningsbruggen S., Navascués J., Lamond A.I. The multifunctional nucleolus. Nat. Rev. Mol. Cell Biol. 2007, 8:574-585.
6. Boisvert F.M., Ahmad Y., Gierlinski M., Charriere F., Lamond D., Scott M., Barton G., Lamond A.I. A quantitative spatial proteomics analysis of proteome turnover in human cells. Mol. Cell. Proteomics 2011, 11. 10.1074/mcp.M111.011429.
7. Boulon S., Ahmad Y., Trinkle-Mulcahy L., Verheggen C., Cobley A., Gregor P., Bertrand E., Whitehorn M., Lamond A.I. Establishment of a protein frequency library and its application in the reliable identification of specific protein interaction partners. Mol. Cell. Proteomics 2010, 9:861-879.
8. Boulon S., Westman B.J., Hutten S., Boisvert F.M., Lamond A.I. The nucleolus under stress. Mol. Cell 2010, 40:216-227.
9. Boyd M.T., Vlatkovic N., Rubbi C.P. The nucleolus directly regulates p53 export and degradation. J. Cell Biol. 2011, 194:689-703.
10. Campbell K.J., Perkins N.D. Post-translational modification of RelA(p65) NF-kappaB. Biochem. Soc. Trans. 2004, 32:1087-1089.
11. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell 2004, 13:853-865.
12. Charfi C., Voisin V., Levros L.C., Edouard E., Rassart E. Gene profiling of Graffi murine leukemia virus-induced lymphoid leukemias: identification of leukemia markers and Fmn2 as a potential oncogene. Blood 2011, 117:1899-1910.
13. Chen X., Barton L.F., Chi Y., Clurman B.E., Roberts J.M. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell 2007, 26:843-852.
14. Chen Z., Carracedo A., Lin H.K., Koutcher J.A., Behrendt N., Egia A., Alimonti A., Carver B.S., Gerald W., Teruya-Feldstein J., et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci. Signal. 2009, 2:ra44. 10.1126/scisignal.2000053.
15. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443:214-217.
16. Culver C., Sundqvist A., Mudie S., Melvin A., Xirodimas D., Rocha S. Mechanism of hypoxia-induced NF-kappaB. Mol. Cell. Biol. 2010, 30:4901-4921.
17. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Bröcker E.B., LeBoit P.E., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353:2135-2147.
18. D'alessandro, M., Vachtsevanos, G., Esteller, R., Echauz, J., Sewell, D., and Litt, B. (2002). A systematic approach to seizure prediction using genetic and classifier based feature selection. Dsp 2002: 14th International Conference on Digital Signal Processing Proceedings, Vols 1 and 2, 603-606.
19. Dominguez-Brauer C., Brauer P.M., Chen Y.J., Pimkina J., Raychaudhuri P. Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle 2010, 9:86-89.
20. Efeyan A., Garcia-Cao I., Herranz D., Velasco-Miguel S., Serrano M. Tumour biology: policing of oncogene activity by p53. Nature 2006, 443:159.
21. Faix J., Grosse R. Staying in shape with formins. Dev. Cell 2006, 10:693-706.
22. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
23. Goldstein A.M., Chan M., Harland M., Hayward N.K., Demenais F., Bishop D.T., Azizi E., Bergman W., Bianchi-Scarra G., Bruno W., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet. 2007, 44:99-106. Lund Melanoma Study Group, Melanoma Genetics Consortium (GenoMEL)Melanoma Genetics Consortium (GenoMEL).
24. Granneman S., Baserga S.J. Ribosome biogenesis: of knobs and RNA processing. Exp. Cell Res. 2004, 296:43-50.
25. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
26. Katoh M., Katoh M. Characterization of FMN2 gene at human chromosome 1q43. Int. J. Mol. Med. 2004, 14:469-474.
27. Lam Y.W., Lamond A.I., Mann M., Andersen J.S. Analysis of nucleolar protein dynamics reveals the nuclear degradation of ribosomal proteins. Curr. Biol. 2007, 17:749-760.
28. Leader B., Lim H., Carabatsos M.J., Harrington A., Ecsedy J., Pellman D., Maas R., Leder P. Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes. Nat. Cell Biol. 2002, 4:921-928.
29. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537.
30. Li X., Amazit L., Long W., Lonard D.M., Monaco J.J., O'Malley B.W. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell 2007, 26:831-842.
31. Lim C.A., Yao F., Wong J.J., George J., Xu H., Chiu K.P., Sung W.K., Lipovich L., Vega V.B., Chen J., et al. Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB upon TLR4 activation. Mol. Cell 2007, 27:622-635.
32. Llanos S., Clark P.A., Rowe J., Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 2001, 3:445-452.
33. Mason S.L., Loughran O., La Thangue N.B. p14(ARF) regulates E2F activity. Oncogene 2002, 21:4220-4230.
34. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
35. Ozenne P., Eymin B., Brambilla E., Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 2010, 127:2239-2247.
36. Pederson T. The nucleolus. Cold Spring Harb. Perspect. Biol. 2011, 3. 10.1101/cshperspect.a000638.
37. Pederson T., Tsai R.Y. In search of nonribosomal nucleolar protein function and regulation. J. Cell Biol. 2009, 184:771-776.
38. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
39. Perkins N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 2012, 12:121-132.
40. Rocha S., Campbell K.J., Perkins N.D. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell 2003, 12:15-25.
41. Rocha S., Garrett M.D., Campbell K.J., Schumm K., Perkins N.D. Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 2005, 24:1157-1169.
42. Schulze A., Lehmann K., Jefferies H.B., McMahon M., Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 2001, 15:981-994.
43. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001, 2:731-737.
44. Soufir N., Lacapere J.J., Bertrand G., Matichard E., Meziani R., Mirebeau D., Descamps V., Gérard B., Archimbaud A., Ollivaud L., et al. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br. J. Cancer 2004, 90:503-509.
45. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998, 17:5001-5014.
46. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 2002, 1602:47-59.
47. Wadhwa R., Sugihara T., Hasan M.K., Taira K., Reddel R.R., Kaul S.C. A major functional difference between the mouse and human ARF tumor suppressor proteins. J. Biol. Chem. 2002, 277:36665-36670.
48. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., Zambetti G.P. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000, 14:2358-2365.
49. Zheng C., Ren Z., Wang H., Zhang W., Kalvakolanu D.V., Tian Z., Xiao W. E2F1 Induces tumor cell survival via nuclear factor-kappaB-dependent induction of EGR1 transcription in prostate cancer cells. Cancer Res. 2009, 69:2324-2331.
50. Zilfou J.T., Lowe S.W. Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 2009, 1:a001883. 10.1101/cshperspect.a001883.